Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib in Advanced Biliary Tract Adenocarcinoma
NCT02346032Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jun 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of refametinib in biliary tract adenocarcinoma, sponsored by Samsung Medical Center. Primary endpoint: Response Rate at 12 months. Started Jun 2015; status: completed.
02
Drugs
refametinib
03
Conditions
biliary tract adenocarcinoma
Beyond the preview
Go deeper on NCT02346032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346032.